ABSTRACT
Objective To evaluate the clinical efficacy and safety of domestic BuMA biodegradable drug eluting coronary stent in elderly coronary heart disease patients over 75 years old with shortened duration of clopidogrel treatment. Methods 100 elderly patients who received coronary angiography and PCI were included, and they were randomly divided into the observation group ( n=50, received oral clopidogrel for 9 months) and the control group (n=50, received oral clopidogrel for 12 months). The occurance of angina pectoris, AMI, bleeding events and the results of control angiography were compared between the two groups after 12 months of follow-up. Results All the 100 patients were followed up in 12 months after discharge. 4 patients ( 8. 0%) in the observation group and 3 patients ( 6. 0%) in the control group had recurrent angina. Control coronary angiography 12 months later showed no restenosis in the stents. There was no significant difference between the two groups in the recurrence of angina pectoris and coronary stent restenonsis. No acute myocardial infarction,cliniacl bleeding events and late stent thrombosis occurred in the two groups. Conclusions The application of the domestic BuMA biodegradable drug eluting stent for the treatment of coronary heart disease patients over 75 years old is safe and effective with shortened duration of clopidogel treatment.
ABSTRACT
AIM: To study the efficacy and adverse reactions of carnitine on patients with acute cerebral infarction. METHODS: One hundred and thirty-five patients with acute cerebral infarction diagnosed by CT or MRI were randomly divided into 2 groups, on the basis of conventional therapy. Sixty-eight patients in carnitine group (M37,F31; age 60 a± s 17 a) received carnitine 2-3g, iv, drip, qd for 28 d. The other 67 patients of control group (M39, F28; age 63 a±17 a) received compound salvia miltirrhiza 20 mL in dextran-40 glucose injection 500 mL, iv, drip, qd for 28 d. RESULTS: The total effective rates of carnitine group and control group for acute cerebral infarction were 80％ and 55％, respectively (P<0.05). No adverse reactions were found. CONCLUSION: Carnitine is safe and effective in the treatment of acute cerebral infarction.